SCHEMBL15216486

SCHEMBL15216486

CC(C)(C)/[N+]([O-])=C/c1cccc(C(F)(F)F)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.54
NFE2L2 Q16236 1/20 0.49
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TTR P02766 1/20 0.38
PIM1 P11309 1/20 0.38
CISD1 Q9NZ45 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
P4HB P07237 1/20 0.38
LMNA P02545 1/20 0.38
HSP90AA1 P07900 1/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HTT P42858 1/20 0.38
THRB P10828 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7922822 0.79 FBP1 (0.49) FBP1NFE2L2MAPK1PKM
SCHEMBL15216495 0.79 FBP1 (0.49) FBP1NFE2L2MAPK1PKM
SCHEMBL15216490 0.79 FBP1 (0.49) FBP1TSHR
SCHEMBL7922827 0.79 FBP1 (0.49) FBP1TSHR
SCHEMBL28566965 0.77 FBP1 (0.50) FBP1NFE2L2TSHRHSP90AA1MAPT
SCHEMBL15216487 0.77 FBP1 (0.50) FBP1NFE2L2TSHRHSP90AA1MAPT
SCHEMBL4711176 0.76 FBP1 (0.49) FBP1TSHRMEN1KMT2ALMNA
SCHEMBL15216509 0.76 FBP1 (0.49) FBP1MEN1KMT2ALMNAHSP90AA1
SCHEMBL11410618 0.75 MAPT (0.59) FBP1NFE2L2TSHRMEN1KMT2A
SCHEMBL6260317 0.74 TDP1 (0.59) FBP1TSHRKMT2AMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130225694-A1 COMPOSITIONS AND METHODS OF INHIBITING RETINAL DEGENERATION OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225694-A1 COMPOSITIONS AND METHODS OF INHIBITING RETINAL DEGENERATION ALDH1A2, PDE6C, NQO1 FBP1 668/4885NFE2L2 179/4885TSHR 4475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.